Highlights

  • CSL reported FY2026 Operating Revenue of US$15,797 million across its three principal Business segments.
  • Underlying NPATA attributable to shareholders reached US$3,098 million, while statutory results reflected significant charges.
  • CSL Behring remained the largest revenue contributor, alongside the Seqirus and Vifor businesses.
  • The company reported restructuring and Impairment expenses of US$7,923 million for the financial year.
  • FY2026 Operating Cash Flow and the annual Dividend provide additional context for the reported Earnings figures.

CSL Limited (ASX:CSL) develops and supplies biotechnology-based medicines, including plasma-derived therapies, influenza vaccines and treatments used in kidney care and iron deficiency. Its operations span CSL Behring, CSL Seqirus and CSL Vifor. For the year ended 30 June 2026, the group reported revenue across these businesses alongside substantial restructuring and impairment expenses, making the distinction between statutory and underlying earnings particularly relevant.

FY2026 Revenue Across Three Businesses

CSL Limited (ASX:CSL) reported total operating revenue of US$15,797 million for FY2026. CSL Behring accounted for US$11,387 million, CSL Vifor for US$2,379 million and CSL Seqirus for US$2,031 million. The segments cover different product markets, including immunoglobulins and other plasma-based medicines, influenza vaccines, and treatments in nephrology and iron deficiency.

Within CSL Behring, immunoglobulins generated US$6,248 million in FY2026 revenue. Other reported categories included haemophilia, albumin, hereditary angioedema and peri-operative bleeding. This range of therapies means the unit’s performance reflects several distinct medical markets rather than a single product category.

Underlying Profit and Statutory Loss

CSL Limited (ASX:CSL) reported underlying net profit after tax and Amortisation (NPATA) attributable to shareholders of US$3,098 million for FY2026. However, statutory net loss attributable to shareholders was US$2,579 million. The difference principally reflects adjustments that include impairment and restructuring charges, as well as amortisation of acquired intellectual property.

The company recorded US$7,923 million in restructuring and impairment expenses in FY2026. These charges materially affected statutory profitability. Underlying earnings and statutory results therefore describe different aspects of the same reporting period and should not be treated as interchangeable.

Cash Flow, Dividends and Capital Management

Operating cash flow for FY2026 was US$3,512 million. CSL Limited (ASX:CSL) maintained total annual dividend payments at US$2.92 per share and completed an A$1 billion share buy-back program. Cash generation, Shareholder distributions and non-cash accounting charges provide separate perspectives on the group’s financial position.

CSL reported Research and Development expenses of US$1,223 million in FY2026. The expenditure relates to work across the company’s research portfolio, while individual program outcomes remain subject to clinical and regulatory processes.

Commercial and Operating Considerations

CSL Limited (ASX:CSL) operates in markets influenced by treatment demand, Manufacturing costs, reimbursement arrangements and healthcare policy. CSL Behring depends partly on plasma collection and processing activities, CSL Seqirus on influenza vaccination demand, and CSL Vifor on competition and access to medicines.

The company identified generic competition affecting its iron products and the Withdrawal of TAVNEOS in European markets among considerations for CSL Vifor. These factors illustrate why operating conditions can differ materially between divisions, even within the same financial year.

Key Insights

FY2026 results show CSL Limited (ASX:CSL) generated revenue and operating cash flow from an established global biotechnology portfolio while reporting a statutory loss affected by restructuring and impairment charges. Its three operating segments have distinct Demand and regulatory conditions. Interpreting the year requires separating divisional activity, underlying profitability, statutory accounting effects and cash generation.